botulinum toxin A alphavaccine

The botulinum toxin A alphavaccine is an investigational biodefense vaccine developed by AlphaVax using its proprietary Viral Replicon Particle (VRP) technology. The platform utilizes a propagation-defective RNA replicon derived from the Venezuelan Equine Encephalitis (VEE) virus to deliver the genetic code for the C-terminal portion of the heavy chain (Hc fragment) of botulinum neurotoxin type A (BoNT/A). This Hc fragment is the non-toxic domain responsible for binding to neuronal receptors. Upon intramuscular injection, the VRPs infect local cells and express the Hc antigen, which triggers a robust immune response. The primary goal is the induction of high titers of neutralizing antibodies that block the toxin's entry into neurons, thereby preventing the paralysis associated with botulism. This RNA-based approach is designed to be more rapid and potentially more effective than traditional toxoid-based vaccines, which require multiple doses and long periods to achieve immunity.

Other names

botulinum toxin A VRP vaccinebotulinum toxin A RNA particle vaccineAlphaVax botulism vaccineVRP-BoNT/A Hc